Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 2249-2259

  Claveria Gimeno, Rafael ^a,b,c   Vega, Sonia ^c   Grazu, Valeria ^c   de la Fuente, Jesús M ^c,d   Lanas, Angel ^b,c,f,g   Velazquez Campoy, Adrian ^b,c,e   Abian, Olga ^a,b,c,f  

^a INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e FUNDACIÓN ARAID   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Antiviral compounds; Cyclodextrins; Drug activity; Drug delivery; Hepatitis C; NS3 protease; Primary and secondary screenings; Vehiculization; Virus replicon system

Indexed keywords

ANTIVIRUS AGENT; GAMMA CYCLODEXTRIN; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; GAMMA CYCLODEXTRIN DERIVATIVE; GAMMA-CYCLODEXTRIN; NS3 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BIOPHYSICS; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HELICOBACTER PYLORI; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LIGAND BINDING; MICHAELIS MENTEN KINETICS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NANOMEDICINE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN FOLDING; THERMODYNAMICS; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG EFFECTS; HEPACIVIRUS; METABOLISM; PRECLINICAL STUDY; PROCEDURES;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; GAMMA-CYCLODEXTRINS; HEPACIVIRUS; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84928137605     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S79480     Document Type: Article

References (54)

1. Inglese J, Johnson RL, Simeonov A, et al. High-throughput screening assays for the identification of chemical probes. Nat Chem Biol. 2007;3:466-479.
2. Bleicher KH, Böhm HJ, Müller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov. 2003;2(5):369-378.
3. Nature Outlook: Hepatitis C. Nature. 2011;474:S1-S21.
4. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5(6):453-463.
5. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol. 2013;58(3):583-592.
6. Bacon BR, Gordon, SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-1217.
7. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.
8. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.
9. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-2428.
10. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(3):736-743.
11. Rosenquist Å, Samuelsson B, Johansson PO, et al. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J Med Chem. 2014;57(5):1673-1693.
12. Sarkar S, Lim JK. Advances in interferon-free hepatitis C therapy: 2014 and beyond. Hepatology. 2014;59(4):1641-1644.
13. Abian O, Neira JL, Velazquez-Campoy A. Thermodynamics of zinc binding to hepatitis C virus NS3 protease: A folding by binding event. Proteins. 2009;77(3):624-636.
14. Abian O, Vega S, Neira JL, Velazquez-Campoy A. Conformational stability of hepatitis C virus NS3 protease. Biophys J. 2010;99(11):3811-3820.
15. Abian O, Vega S, Sancho J, Velazquez-Campoy A. Allosteric Inhibitors of the NS3 Protease From the Hepatitis C Virus. PLoS One. 2013;8(7):e69773.
16. Li S, Purdy WC. Cyclodextrins and their applications in analytical chemistry. Chem Rev. 1992;92(6):1457-1470.
17. Villiers A. Sur la fermentation de la fecule par l'action du ferment butyrique [The fermentation of starch by the action of butyric]. C R Acad Sci. 1981;112:536-538. French.
18. Saenger W. Cyclodextrin inclusion compounds in research and industry. Angew Chem Int Ed Engl. 1980;19(5):344-362.
19. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98(5):2045-2076.
20. Singh M, Sharma R, Banerjee UC. Biotechnological applications of cyclodextrins. Biotechnol Adv. 2002;20(5-6):341-359.
21. Villalonga R, Cao R, Fragoso A. Supramolecular chemistry of cyclodextrins in enzyme technology. Chem Rev. 2007;107(7):3088-3116.
22. Rekharsky MV, Inoue Y. Complexation thermodynamics of cyclodextrins. Chem Rev. 1998;98(5):875-1917.
23. Fuchs R, Habermann N, Klufers P. Multinuclear sandwich-type complexes of deprotonated β-cyclodextrin and copper(II) ions. Angew Chem Int Ed Eng. 1993;32(6):852-854.
24. Irie T, Uekama K. Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev. 1999;36(1):101-123.
25. Lysik MA, Wu-Pong S. Innovations in oligonucleotide drug delivery. J Pharm Sci. 2003;92(8):1559-1573.
26. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86(2):147-162.
27. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007;59(7):645-666.
28. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release. 2007;123(2):78-99.
29. Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev. 1999;36(1):125-141.
30. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present, and future. Nat Rev Drug Discov. 2004;3(12):1023-1035.
31. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J Pharm Pharmacol. 2011;63(9):1119-1135.
32. Matsuda H, Arima H. Cyclodextrins in transdermal and rectal delivery. Adv Drug Deliv Rev. 1999;36(1):80-99.
33. Loftsson T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev. 1999;36(1):59-79.
34. Merkus FW, Verhoef JC, Marttin E, et al. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev. 1999;36(1):41-57.
35. Szente L, Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev. 1999;36(1):17-28.
36. Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting application to nanoparticles. Adv Drug Deliv Rev. 1999;36(1):29-40.
37. Sinha VR, Nanda A, Kumria R. Cyclodextrins as sustained-release carriers. Pharmaceutical Technology. 2002;44:36-44.
38. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329(1-2):1-11.
39. Fini P, Castagnolo M, Catucci L, Cosma P, Agostiano A. Inclusion complexes of Rose Bengal and cyclodextrins. Thermochim Acta. 2004;418:33-38.
40. Sun DZ, Qiu XM, Li L, Wei XL, Yin BL. A study of a-cyclodextrin with a group of cationic Gemini surfactants utilizing isothermal titration calorimetry and NMR. J Chem Thermodyn. 2006;38(6):773-777.
41. Liu Y, Cao R, Chen Y, He JY. Effect of b-cyclodextrin charge type on the molecular recognition thermodynamics of reactions with (ferrocenylmethyl)dimethylaminium derivatives. J Phys Chem B. 2008;112(5):1445-1450.
42. Denadai AM, Teixeira KI, Santoro MM, Pimenta AM, Cortes ME, Sinisterra RD. Supramolecular self-assembly of b-cyclodextrin: an effective carrier of the antimicrobial agent chlorhexidine. Carbohydr Res. 2007;342(15):2286-2296.
43. He Y, King MS, Kempf DJ, et al. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother. 2008;52(3):1101-1110.
44. Cremades N, Velazquez-Campoy A, Martinez-Julvez M, et al. Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection. ACS Chem Biol. 2009;4(11):928-938.
45. Pey AL, Ying M, Cremades N, et al. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J Clin Invest. 2008;118(8):2858-2867.
46. Taliani M, Bianchi E, Narjes F, et al. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Anal Biochem. 1996;240(1):60-67.
47. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639-1662.
48. Solis FJ, Wets RJ. Minimization by Random Search Techniques. Mathematics of Operations Research. 1981;6:19-30.
49. Courcambeck J, Bouzidi M, Perbost R, et al. Resistance of hepatitis C virus to NS3-4A protease inhibitors: Mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antivir Ther. 2004;11(7):847-855.
50. Susser S, Vermehren J, Forestier N, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol. 2011;52(4):321-327.
51. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76(24):13001-13014.
52. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285(5424):110-113.
53. Urbani A, Bazzo R, Nardi MC, et al. The metal binding site of the hepatitis C virus NS3 protease. A spectroscopic investigation. J Biol Chem. 1998;273(30):18760-18769.
54. Vega S, Neira JL, Marcuello C, et al. NS3 protease from hepatitis C virus: Biophysical studies on an intrinsically disordered protein domain. Int J Mol Sci. 2013;14(7):13282-13306.